Name (Synonyms) | Correlation |
---|
There is one clinical trial.
A novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) disease (COVID-19) emerged at December 2019 in Wuhan, China, and soon caused a large global outbreak. The delayed treatment for many chronic diseases, due to the concern of SARS-CoV-2 infection, is an increasing serious problem. Here we investigate the safety of chemotherapy for patients with gynecological malignancy in Wuhan, the center of high-risk regions of COVID-19.
Description: Incidence rate of SARS-CoV-2 infection within the whole period of the study.
Measure: SARS-CoV-2 infection Time: through study completion, an average of 3 months.Description: Tumor response by determining changes (PD, SD, PR, CR) according to Response Evaluation Criteria in Solid Tumours (RECIST), version 1.1
Measure: Tumor response Time: 6 weeks after enrollment.Description: Safety and tolerability of chemotherapy as measured by the Common Terminology Criteria for Adverse Events (version 4.0)
Measure: Safety and tolerability Time: through study completion, an average of 3 months.Description: Patient-reported outcomes are measured using the EORTC quality of life questionnaire core-30 (QLQ-C30).
Measure: Patient-reported outcomes Time: through study completion, an average of 3 months.